<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541007</url>
  </required_header>
  <id_info>
    <org_study_id>2011-004178-27</org_study_id>
    <nct_id>NCT01541007</nct_id>
  </id_info>
  <brief_title>A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer</brief_title>
  <acronym>ConCab</acronym>
  <official_title>A Randomized, Open Label, Multicenter, Phase II Trial Comparing The Conventional 3 Weekly Schedule Of Cabazitaxel With A Weekly Regimen In Patients With Metastatic Castration Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Yachnin M.D., PhD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cabazitaxel has shown significant efficacy as second line chemotherapy after Docetaxel in men&#xD;
      with metastatic castration resistant prostate cancer. This was demonstrated in the Tropic&#xD;
      Study where Cabazitaxel showed survival superiority compared to mitoxantrone. Almost one in 4&#xD;
      patients treated with Cabazitaxel in this study required dose reductions or dose delays or&#xD;
      stopped treatment due to toxicity. ConCab examines another scheduling for cabazitaxel to see&#xD;
      if we can improve tolerability so that patients will receive a higher percentage of the&#xD;
      treatment as planned.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ConCab compares the standard treatment of cabazitaxel 25 mg/m2 every three weeks with an&#xD;
      experimental scheduling of 10 mg/m2 for 5 consecutive weeks of a 6 week cycle. In both study&#xD;
      arms the planned cumulative dose of cabazitaxel at week 18 is 150 mg/m2. Our study aims to&#xD;
      evaluate differences in the total received dose in relation to the planned dose as a measure&#xD;
      of which of the 2 treatment schedules is superior.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative cumulative dose of cabazitaxel at week 18</measure>
    <time_frame>week 18 after start of treatment</time_frame>
    <description>The primary endpoint compares the cumulative dose of cabazitaxel that is received relative to the planned dose at 18 weeks of therapy. The cumulative dose of cabazitaxel in relation to the expected dose is a reflection of both tolerability and efficacy. Patients stopping treatment due to disease progression prior to week 18 will have lower relative cumulative doses as will patients with poor tolerability due to dose reductions and delays.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>when the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date</time_frame>
    <description>Overall survival is defined as the length of time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>when the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date</time_frame>
    <description>Progression free survival is defined as the length of time from randomisation to the first documentation of one of the following: PSA progression or pain progression or death due to any cause or radiological disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Response</measure>
    <time_frame>when the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date</time_frame>
    <description>Only considered after 12 weeks of treatment. PSA response is defined as a 50% or greater decline in serum PSA from baseline given that baseline PSA is at least 10 ng/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Cabazitaxel Schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cabazitaxel 25 mg/m2 every three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weekly cabazitaxel schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>25 mg/m2 every three weeks</description>
    <arm_group_label>Standard Cabazitaxel Schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>weekly cabazitaxel</intervention_name>
    <description>10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks</description>
    <arm_group_label>Weekly cabazitaxel schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Â¨&#xD;
&#xD;
          -  Histological confirmed prostate cancer&#xD;
&#xD;
          -  Macroscopic metastatic disease&#xD;
&#xD;
          -  Prior treatment with Docetaxel&#xD;
&#xD;
          -  Castration resistant disease defined as:Serum testosterone (&lt; 0.5 ng/ml) and:&#xD;
&#xD;
          -  Increase in measurable disease (RECIST 1.1, see appendix 10) or&#xD;
&#xD;
          -  For non-measurable disease, the appearance of at least one new lesion on nuclear&#xD;
             scintigraphy) or&#xD;
&#xD;
          -  A rising PSA from the previous reference value on 2 consecutive occasions at least one&#xD;
             week apart&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 21 days since prior treatment with chemotherapy&#xD;
&#xD;
          -  Less than 14 days since radiotherapy or surgery to the start of cabazitaxel - Less&#xD;
             than 4 weeks after stopping endocrine therapies including antiandrogen, abiraterone or&#xD;
             other new agents.&#xD;
&#xD;
          -  Prior isotope therapy or radiotherapy to &gt; 30% of bone marrow (whole pelvic&#xD;
             radiotherapy is not an exclusion criteria)&#xD;
&#xD;
          -  Persistent adverse events from previous cancer therapies &gt; grade 1 (CTCAE - Version&#xD;
             4.0) with the exception of alopecia. (With respect to peripheral neuropathy and nail&#xD;
             changes grade 2 is acceptable)&#xD;
&#xD;
          -  ECOG performance status &gt; 1&#xD;
&#xD;
          -  Known CNS malignancy&#xD;
&#xD;
          -  Within 6 months of randomization:&#xD;
&#xD;
               -  myocardial infarction,&#xD;
&#xD;
               -  unstable angina,&#xD;
&#xD;
               -  angioplasty,&#xD;
&#xD;
               -  bypass surgery,&#xD;
&#xD;
               -  stroke,&#xD;
&#xD;
               -  TIA, or&#xD;
&#xD;
               -  congestive heart failure NYHA class III or IV&#xD;
&#xD;
          -  Within 3 months prior to randomization:&#xD;
&#xD;
               -  treatment resistant peptic ulcer disease,&#xD;
&#xD;
               -  infectious or inflammatory bowel disease,&#xD;
&#xD;
               -  pulmonary embolism&#xD;
&#xD;
               -  Any severe acute or chronic medical condition that places the patient at&#xD;
                  increased risk of serious toxicity or interferes with the interpretation of study&#xD;
                  results&#xD;
&#xD;
          -  History of hypersensitivity to docetaxel or polysorbate 80&#xD;
&#xD;
          -  Inadequate organ and bone marrow function as evidenced by:&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1.5 x 109/L,&#xD;
&#xD;
               -  Platelet count &lt; 100 x 109/L,&#xD;
&#xD;
               -  AST/SGOT and/or ALT/SGPT &gt; 1.5 x ULN;&#xD;
&#xD;
               -  Total bilirubin &gt; 1.0 x ULN,&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance&#xD;
                  will be calculated according to CKD-EPI formula and patients with creatinine&#xD;
                  clearance &lt; 60 mL/min should be excluded (http://mdrd.com/ for on-line&#xD;
                  calculation)&#xD;
&#xD;
          -  Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450&#xD;
             3A4/5. A one week wash out period is necessary for patients who are already on these&#xD;
             treatments.&#xD;
&#xD;
          -  Patients with reproductive potential not implementing accepted and effective method of&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey R Yachnin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska University Hosptial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deapartment of Oncology Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jeffrey Yachnin M.D., PhD.</investigator_full_name>
    <investigator_title>Director Clinical Trials Unit</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Castration Resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

